Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PAXG
- Development stage
- Phase 3
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous (nab-paclitaxel, Gemcitabine, Cisplatin), Oral (capecitabine)
01
Overview
PAXG is a combination chemotherapy regimen used in the treatment of advanced pancreatic adenocarcinoma. The acronym "PAXG" stands for a four-drug combination consisting of nab-paclitaxel (Abraxane), gemcitabine, capecitabine (Xeloda), and cisplatin. This regimen has been investigated in clinical trials for its efficacy and safety in patients with stage III-IV pancreatic cancer. Each component acts via different mechanisms to inhibit tumor growth and proliferation: - Nab-paclitaxel is a microtubule inhibitor. - Gemcitabine is a nucleoside analog that inhibits DNA synthesis. - Capecitabine is an oral prodrug converted to 5-fluorouracil, which inhibits thymidylate synthase. - Cisplatin forms DNA crosslinks, leading to apoptosis.
- Brand names
- PAXG
- Other names
- PAX-GPAXG
02
Targets
MicrotubuleTS (Thymidylate synthase)DNARNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on PAXG.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PAXG.